From: Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer
Parameters | Â |
---|---|
Cmax(%IA/g) | 47.83 ± 22.38 |
Cl(ml/h) | 0.22 ± 0.07 |
AUC0→∞(%IA/g*h) | 733.09 ± 125.00 |
T1/2Z(h) | 67.81 ± 21.54 |
MRT0→∞(h) | 78.53 ± 21.79 |